Fulcrum Therapeutics, Inc.

Fulcrum did not report product revenue, but it did report first-quarter 2026 operating results. Research and development expense was $14.1 million versus $13.4 million in the first quarter of 2025, general and administrative expense was $8.1 million versus $7.0 million, and net loss was $22.2 million versus $20.4 million a year ago. Cash, cash equivalents and marketable securities were $333.3 million at March 31, 2026, down from $352.3 million at December 31, 2025; management said this should fund operations into 2029. On the clinical side, management highlighted the Phase 1b PIONEER result of HbF rising from 7.1% to 19.3% after 12 weeks on 20 mg daily, with 7 of 12 patients experiencing no VOCs during treatment. Forward-looking guidance: Fulcrum expects to provide an update on the next pociredir trial design later this quarter after its upcoming FDA end-of-phase meeting and receipt of final minutes. Pending FDA feedback, the company plans to initiate a potential registration-enabling trial in the second half of 2026. Management also said it expects to interact with EMA later this year as part of a likely global development path.

Alex Sapir framed the quarter as an inflection point for Fulcrum, pointing to the PIONEER data as evidence that pociredir can address the underlying biology of sickle cell disease. His tone was confident and strategic: he emphasized the high unmet need, the link between fetal hemoglobin and reduced VOCs, and the company’s belief that an oral HbF inducer could become an important treatment option. He also stressed operational readiness, citing a strong balance sheet, the upcoming FDA meeting, and a plan to move toward a registration-enabling study.

Alan Musso focused on the quarterly financials and runway. He said R&D expense was $14.1 million in Q1 2026 versus $13.4 million in Q1 2025, with the increase mainly from higher employee compensation and $400,000 of increased stock-based compensation; G&A was $8.1 million versus $7.0 million, driven by higher compensation, $300,000 of increased stock-based compensation, and professional services. Net loss was $22.2 million versus $20.4 million, and cash, cash equivalents and marketable securities totaled $333.3 million at quarter-end versus $352.3 million at year-end 2025. He said current cash should be sufficient to fund operating requirements into 2029.

Analysts focused on what Fulcrum learned from PIONEER, the regulatory path for HbF as a surrogate endpoint, the open-label extension, competition, and combination strategies. Management said the biggest learnings were the persistent high unmet need in severe sickle cell disease and the strong relationship between higher HbF and lower VOCs; on regulation, they said the surrogate-endpoint question will be discussed with FDA and that the company aims to design a robust study demonstrating clinical benefit. On the open-label study, management said it is enrolling the 17 U.S. patients from Cohorts 3b and 4 over time, with meaningful longer-duration data more likely in 2027 rather than at ASH 2026. They also said the next-stage global program will involve EMA later this year, and that combination work may be considered later, but the current priority is an interpretable monotherapy data set supporting registration.